# Study of M5049 in DM and PM Participants (NEPTUNIA)

> **NCT05650567** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Dermatomyositis
- Polymyositis

## Interventions

- **DRUG:** M5049 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05650567
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-19
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Based on interim analyses for futility
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650567, "Study of M5049 in DM and PM Participants (NEPTUNIA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05650567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*